Investigational drug · Phase 2
HMB-002
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "HMB-002"
First trial start
2025
Feb 6, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HMB-002", any sponsor or status.
Conditions studied
As listed on its trial records.
- Von Willebrand Disease (VWD)
- Von Willebrand Disease (VWD), Type 1
- Von Willebrand Disease (VWD), Type 2
- Von Willebrand Disease (VWD), Type 3
Approved drugs for the same conditions: Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "HMB-002" as an intervention, largest first.
Hemab ApSIndustry
NCT06754852 · 108 participants (planned) · Start Feb 6, 2025 · Primary completion Jul 2027
Drug: HMB-002 (Part A); HMB-002 (Part B) and 1 more · For: Von Willebrand Disease (VWD); Von Willebrand Disease (VWD), Type 1; Von Willebrand Disease (VWD), Type 2 and 1 more
Sites: Phoenix, Arizona; Little Rock, Arkansas; Los Angeles, California · 25 sites in all
- Hepatocyte Microbeads for Acute Liver FailureStatus unknown
King's College Hospital NHS TrustAcademic, hospital or other
NCT05491135 · 17 participants (planned) · Start Sep 2022 · Primary completion Nov 2025
Drug: HMB002 · For: Acute Liver Failure
Newest research
PubMed records naming it or its code names, newest first.
- HMB-002: a monovalent antibody that elevates circulating VWF and FVIII levels for treatment of von Willebrand disease.
Häger M, Zivkovic M, Gandhi PS, et al. · Blood Adv 2026
Also in development for Von Willebrand Disease (VWD)
- SR604Phase 34 trials
Shanghai RAAS Blood Products Co., Ltd. · Factor VII Deficiency, Hemophilia A, Hemophilia B
- VGA039Phase 32 trials
Vega Therapeutics, Inc · Von Willebrand Diseases, Von Willebrand Disease (VWD)
- ALN-6400Phase 22 trials
Alnylam Pharmaceuticals · Von Willebrand Disease (VWD), Heavy Menstrual Bleeding (HMB), Hereditary Hemorrhagic Telangiectasia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.